Document Detail


Antibody against oxidized low density lipoprotein may predict progression or regression of atherosclerotic coronary artery disease.
MedLine Citation:
PMID:  11401125     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: This study aimed to elucidate whether an antibody against oxidized low density lipoprotein (anti-Ox-LDL) could predict short-term coronary artery atherosclerotic lesion progression. BACKGROUND: It is still controversial whether higher levels of the anti-Ox-LDL titer are associated with atherosclerotic coronary artery disease. METHODS: In 52 patients undergoing coronary angioplasty and six-month follow-up angiography, we performed quantitative coronary angiographic analysis of a lesion on a branch away from the intervention site vessel and assessed lesion progression or regression using the Progression-Regression score calculated as the baseline minimal lumen diameter minus the follow-up minimal lumen diameter. The serum anti-Ox-LDL titer was measured using an enzyme-linked immunosorbent assay method just before the initial angiography in all patients. RESULTS: The anti-Ox-LDL titer was 16.6+/-1.5 AcU/ml in the progression group (Progression-Regression score >0.15 mm; n = 20), which was significantly higher (p < 0.001) than the value of 9.5+/-1.2 in the regression group (< or =-0.15 mm; n = 14) and also higher (p < 0.01) than the value of 11.4+/-1.3 in the no-change group (-0.15 to 0.15 mm; n = 18). The Progression-Regression score was correlated with the antibody titer in all patients (r = 0.56, p < 0.001). Multiple regression analysis showed that the Progression-Regression score was independently correlated with the antibody titer (r = 0.44, p < 0.01) as well as lipoprotein (a) (r = 0.33, p < 0.05). CONCLUSIONS: Anti-Ox-LDL may be an independent predictor of coronary atherosclerotic lesion progression in the short term.
Authors:
T Inoue; T Uchida; H Kamishirado; K Takayanagi; S Morooka
Related Documents :
19080725 - Should we treat all patients with coronary heart disease or the equivalent with statins?
17077375 - Statin therapy and risks for death and hospitalization in chronic heart failure.
6386225 - Thirty-five years of progress in cardiovascular research.
15944615 - Cardiovascular risk prevention in peripheral artery disease.
12515735 - Aspirin alters the cardioprotective effects of the factor xiii val34leu polymorphism.
16885425 - Motor recovery as assessed with isometric finger movements and perfusion magnetic reson...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  37     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2001 Jun 
Date Detail:
Created Date:  2001-06-12     Completed Date:  2001-08-09     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1871-6     Citation Subset:  AIM; IM    
Affiliation:
Department of Cardiology, Koshigaya Hospital, Dokkyo University School of Medicine, Saitama, Japan. inouet@dokkyomed.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies / blood*
Coronary Artery Disease / blood,  metabolism*,  radiography*
Disease Progression
Female
Humans
Lipoproteins, LDL* / immunology*,  metabolism*
Male
Middle Aged
Oxidation-Reduction
Predictive Value of Tests
Prognosis
Remission, Spontaneous
Chemical
Reg. No./Substance:
0/Antibodies; 0/Lipoproteins, LDL

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Plaque distribution and vascular remodeling of ruptured and nonruptured coronary plaques in the same...
Next Document:  Percutaneous and surgical interventions for in-stent restenosis: long-term outcomes and effect of di...